This clinical trial is focused on studying a type of cancer known as oligometastatic pancreatic cancer. This condition involves cancer that has spread from the pancreas to a limited number of other areas, such as the liver. The trial aims to compare two different treatment approaches to see which one is more effective in improving the survival of patients. One group of patients will receive a combination of medications known as mFOLFIRINOX, which includes Oxaliplatin, Fluorouracil, Calcium Folinate, and Irinotecan. These medications are given through an injection into a vein. The other group will receive the same combination of medications followed by surgery to remove the cancer.

The purpose of the study is to determine if patients who receive the combination of medications followed by surgery have a better chance of living longer compared to those who receive only the medication. The study will involve regular visits to the clinic for treatment and monitoring. Patients will be randomly assigned to one of the two groups, and some may receive a placebo as part of the study. The study will last for a period of up to 24 months, during which patients will be closely monitored for any changes in their condition and any side effects from the treatment.

Throughout the study, the health and quality of life of the participants will be assessed. This includes looking at how long patients live without the cancer getting worse and any complications that may arise from the treatments. The study will also evaluate the safety of the treatments, including the surgical removal of the tumor and any cancer that has spread. The goal is to gather information that could help improve treatment options for patients with oligometastatic pancreatic cancer in the future.